Outsider Club: Retire Early From the Death of Monsanto

Retire Early From the Death of Monsanto

A tiny biotech controls agricultural technology that could end food shortages forever... And, in the process, render Monsanto GMOs obsolete.
This development stands to make early investors 181 times their money in just a few years.
It's why Citigroup, Wells Fargo, and other financial powerhouses have teamed up to launch the little company that's responsible for all of it.
And you can get in on the action, too. But time’s running out...

double-down-arrow-white

An Ohio wheat farmer frets as he surveys his drought-stunted crop...

A Costa Rican coffee baron lays off hundreds of workers because a fungus spoiled his harvest...

A Nigerian peasant wearily digs up shrunken yams...

It’s the same story all over the world — Irish potatoes, Nebraska corn, Indonesian rice — crops everywhere are under siege by pests, pollution, spores, drought, and more...

But a little biotech that went public just a few short weeks ago has developed technology that can protect our precious crops from these environmental disasters.

Like potatoes that can keep for weeks in the refrigerator...

And low-gluten wheat that can withstand herbicides...

All that’s just for starters. In fact...
This technology can be used on virtually any crop.

And it has the power to end food shortages forever through exploding crop yields.

This is great news for the world’s burgeoning population — not to mention for investors who get in on this company before the Wall Street herd wakes up to it.

The stock recently went public, and those who bought shares the day of its IPO made gains up to 28% by the close.

But this is just a drop in the bucket compared to what I'm expecting this company to do for early investors.

In fact, I believe it could fund your early retirement with a payout I’ve calculated to be worth up to 181 times your money — a gain that would turn every $1,000 invested into a cool $181,000.

Now, I didn’t come up with that figure out of thin air.

And I’ll explain how I arrived at it in just a moment.

But first, I want to touch on something critical for you to understand.

The technology this company has developed is rendering GMOs obsolete.

And I believe that it will be the end of Monsanto as we know it.

Now, I know you may find it hard to believe that a tiny company hardly anyone has ever heard about could solve world hunger and kill Monsanto — a $51.7 billion behemoth.

Nevertheless, I want you to hear me out. I promise it’ll be worth your while...
Monsanto is the "world’s most evil company."

double-down-arrow-white

The agrochemical giant earned this dubious designation in a 2013 poll from Natural News.

But it's not just because of its GMO seeds...

People all over the world hate Monsanto because of the way it uses those seeds to boost sales of its herbicide, Roundup.

See, Monsanto developed its seeds to be resistant to Roundup. It did this by inserting genes from bacteria into the seeds to render them immune to the herbicide's lethal effects.

Result: Every plant the weed killer is sprayed on dies, except for the crops that sprout from those genetically modified seeds.

This makes for bigger yields and saves farmers considerable labor since they don’t have to till the soil.

Obviously, all of this translates into more income for them.

But there’s a huge catch...
It’s a deal with the devil.

And I call it one because farmers have to sign a contract promising they won’t plant seeds that develop from Monsanto GMO crops.

They're also not allowed to save, sell, or give these seeds away. This essentially forces them to buy a new batch of seeds every year.

And of course, they have to continue using Roundup in order to keep the weeds away.

Unfortunately...
The weeds that are killed by Roundup eventually begin to develop a resistance to it.

When Monsanto and other agribusiness corporations first brought glyphosate — an herbicide that’s the main ingredient in Roundup — to market, the company said targeted weeds would take many years to develop a resistance to it.

But this isn't what’s happening.

Within about three years, signs of glyphosate resistance spreading to weed species began emerging.

This shouldn't surprise anyone as it’s common for targeted weeds to develop a resistance to widely used herbicides and pesticides.

Now, the problem is growing out of control, as the chart below shows:

tao-death-monsanto-states

As you can see, the chart shows how, throughout the U.S., horseweed — a common weed on American farms — is becoming ever more resistant to glyphosate.

Now, check out this graph. It illustrates the massive increase in glyphosate use in the U.S. from 1992 to 2014:

tao-death-monsanto-agricultural

Again, it’s clear as day that the amount of cropland getting doused with glyphosate has exploded since 1992.

Here’s yet another sobering illustration that breaks down usage by year and crop type:

tao-death-monsanto-pounds

So, not only is glyphosate use growing exponentially throughout the U.S., but it’s also spreading to more and more different kinds of crops.
Bottom line: Glyphosate is everywhere.

Since the first use of Roundup in 1974, 3.5 billion lb. of glyphosate — about 20% of total global production — have been sprayed, injected, poured, or sprinkled on U.S. soil and plant life.

This is more than in any other country.

And it's in a country with less than 5% of the world’s population!

Traces of glyphosate have been detected in all four corners of the globe — even in German beer, which, by law for the last 500 years, is only supposed to contain barley, hops, and water.

It’s been found in breakfast cereals, bagels, cookies, crackers, chips, and even in supposedly “healthy” products like Kashi GoLean.

And unsurprisingly, residues have been found in all foods that contain GMO corn and soybeans.

In America, this is a lot of food.

So, chances are that you’re absorbing glyphosate, no matter how healthily you eat.

In Germany, a random 2016 survey of ordinary people found that 99.6% of them had glyphosate coursing through their veins and in their urine.

And since the U.S uses more glyphosate than any other country, it stands to reason that virtually every American has the chemical in their bodies, as well.

This is troubling because...
The World Health Organization says glyphosate exposure increases our risk of cancer.

Evidence of the chief ingredient in Roundup — glyphosate — causes cancer is growing.

In fact, in March of 2015, the International Agency Research on Cancer (IARC), an arm of the World Health Organization (WHO), labeled Roundup as a "probable" human carcinogen.

This statement came out behind a rigorous review process involving new scientific evidence.

It was a huge announcement because the IARC is an arm of the WHO that has a reputation for rigorous and impartial analysis.

The prestigious International Journal of Cancer, Occupational and Environmental Medicine, and Cancer Epidemiology Biomarkers also cited studies that paint Roundup as a likely carcinogen.

These studies have found evidence linking Roundup to the following diseases:

    Bone cancer
    Colon cancer
    Kidney cancer
    Liver cancer
    Leukemia
    Melanoma
    Pancreatic cancer
    Thyroid cancer
    Parkinson's disease.

Unsurprisingly, Monsanto denies these links and points to outdated industry studies as “proof” that Roundup is safe.

Yet, even one of its own scientists said Monsanto can't claim that Roundup doesn't cause cancer.

"We have not done the necessary testing on the formulation to make that statement," Monsanto scientist Dr. Donna Farmer said in a leaked in-house email.

Can you see why Natural News labeled Monsanto as the evilest company in the world?

Well, here’s another reason...
Monsanto is sowing seeds of fear.

double-down-arrow-white

Remember that “no seed planting” rule that I told you about earlier? Well, Monsanto is beyond ruthless in enforcing it.

Gary Rinehart discovered this firsthand.

Back in the summer of 2002, a stranger barged into his little country store in Eagleville, Missouri — a tiny farming community about 100 miles north of Kansas City, Missouri.

He loudly asked for Rinehart by name. And when Rinehart came forward, the man shouted that he had proof of Rinehart having planted Monsanto’s genetically modified soybeans — a violation of Monsanto’s patent.

Rinehart told the man that he’d done no such thing, but the man still insisted that he had. And the man demanded that Rinehart settle with Monsanto immediately or suffer the consequences.

This man was Jeffrey Moore, and he was one of what fearful farmers have dubbed “the seed police” — men paid by Monsanto to secretly spy on (and even videotape) farmers, store owners, and co-ops.

In the case of Rinehart, Moore had targeted the wrong man.

So, Monsanto dropped the suit it had filed against him but not before Rinehart had spent considerable time and money on his defense.

You’d think that Monsanto would have sent a letter of apology or confessed publicly that the company had made a terrible mistake, but you’d be wrong.

The company simply ignored the incident.

As for its heavy-handed enforcement tactics, Monsanto argued that it was simply protecting its patents.

So, the company thinks nothing of suing farmers and store owners whom it believes have violated the agreement.

Result: The accused all too often settle out of court to avoid a lengthy legal fight — even if they’re innocent.

You can’t really blame them.

Who could afford to fight Monsanto — a $51.7 billion company with an army of lawyers?

No one I know.

What Monsanto's doing is pure evil.

Monsanto is polluting the world’s air and water with glyphosate, a suspected carcinogen that’s the main ingredient in Roundup.

The company has sued hundreds of farmers and store owners, causing financial hardship and fear throughout America’s heartland.

And it's trying to monopolize the first link in the food chain — crop seeds.

But there’s a bright side to the terrible deeds of this heartless corporation: It's sown the seeds of its own death.

And you can play a role in accelerating its demise and, in the process, fund your early retirement.

All you have to do is claim a stake in the little biotech that’s making Monsanto obsolete.

Do this and you could make 181 times your money.

That’s 18,100%.

Some of the world’s biggest banks — including Citigroup, Wells Fargo, and Jefferies — are already in position to reap this coming windfall.

And get this, right now, you can get shares of the biotech behind it for about $10.

But a word of warning: As mainstream investors realize the profit potential of this little company, that stupidly cheap price will be gone.

I'm going to reveal how this company’s technology will be the Death of Monsanto in just a moment.

And I'm also going to show you how I arrived at that 181-to-1 profit figure.

But first, I want to address something that’s probably on your mind...
Why you should seriously consider what I have to say.

Imagine getting paid to test out disruptive technologies before they hit the market.

And that, in the course of the work, you develop a wealth of high-tech connections to point you toward incredible breakthroughs ahead of the crowd.

Think this would give you an edge in the markets? You bet it would.

Well, that's my world.

I’m Jason Stutman, the senior technical analyst for Angel Publishing — one of the most respected financial publishers in the world.

Surgical robots, miniature drones, the next generation of 3-D printers, and everything in between, I’ve been fortunate enough to test countless different kinds of disruptive technologies when they're in their early stages.

And when I find one with blockbuster potential, I perform a rigorous analysis to see if the company developing it is worthy of investment.

I leave no stone unturned in this vetting process, asking:

    Does the company have strong growth prospects? If not, forget it.

    Does it have the cash — or access to it — to fund its research?

    Is there a catalyst that can boost prices quickly? Like a potential buyout or a pending regulatory ruling?

Even more importantly in this process, I talk to management to see if it's up to my standards:

    Has it had any big successes? If so, I want to know how they came about. I don’t want to invest in a one-trick pony.

    Is it putting its money where its mouth is? A prime metric is whether management members are buying shares of their own company.

    Does it have a proven record of successfully navigating financial, regulatory, legal, and accounting issues? I’ll avoid the company if there’s even a hint of past trouble here.

    What are its plans for accelerating growth? It’s especially positive if larger cap companies are helping to bring its products to market.

    Does it put shareholders first? Or does it instead reward its own management members at the expense of its shareholders?

If these questions aren’t answered to my satisfaction, I steer clear.

Frankly, that’s usually what happens.

Only companies that pass my analysis get a "Buy" recommendation from me, which I’d say happens with about 1 in 100 companies.

And there's also something else you should know...

Over the last few years, I’ve built a network of professional connections that give me — and those who take my advice — a huge edge with technology investing.

These connections include brilliant researchers, chief technology officers, investor relations executives, and even internationally renowned CEOs.

Now, I can’t drop any names, as that would jeopardize these connections.

And I don’t tell you all of this to brag, just to drive this point home...
My vetting process and industry connections help me find technology plays with a high probability of success.

These include recent gains in biotechnology, like this pioneer in molecular information platforms:

tce-tiny-dots-fmi

And this biotech that's making breakthroughs in diabetes treatments:

tce-tiny-dots-mnkd

And this developer of drugs for neurodegenerative disease:

tce-tiny-dots-pran

We also took juicy, double-digit profits from this orthopedic medicine maker (twice):

tao-death-monsanto-anik
I take profits anywhere in the world of tech.

double-down-arrow-white

I cover the entire world of technology and take profits wherever they present themselves.

Like this leader in industrial robotics:

tce-tiny-dots-adep

And this company that's disrupting the commercial print industry:

tce-tiny-dots-avt

This creator of technology platforms for the medical cannabis community rewarded us very quickly:

tce-tiny-dots-msrt

As did this developer of advanced digital imaging technologies:

tce-tiny-dots-ovti

These were all great plays. But they don’t compare to the profits that I see coming from the company that is rendering Monsanto obsolete.

I expect it to be...
The most profitable technology play of my life.

Picture editing a document on your computer... You see a phrase that you don’t like, so you highlight and delete it.

Well, this analogy is the easiest way to explain how the technology of the little biotech I’ve been telling you about works.

It’s called gene editing.

You simply “snip” parts of a plant’s DNA that are responsible for an unwanted trait and presto — the trait no longer exists.

Want drought-resistant corn?

Snip!

Want to make your soybeans immune to blight?

Snip!

Want to create wheat that uses its own immune system to repel pests?

Snip!

So far, the little $10 company has used this gene-editing technology to develop food products that are near commercialization, including...

    Potatoes that you can store in the refrigerator, making them last far longer after you buy them.

    Wheat that could produce flour with up to three times more dietary fiber than the standard, thereby improving digestion, lowering cholesterol, stabilizing glucose levels, and helping to keep weight down.

    Reduced trans fat in soybean oil and lower saturated fat in canola oil, which studies show can lower the risk of heart disease.

    Wheat, corn, and rice that are immune to the devastating powdery mildew disease, resulting in farmers being able to forgo poisonous herbicides.

But this company has many more food products in the pipeline, like...

    Herbicide-tolerant wheat. This alone could be the death knell for Monsanto, as it will render GMO seeds obsolete and also drastically reduce the need for Roundup and other herbicides.

    Gluten-reduced wheat, a godsend for bread lovers with gluten sensitivities.

    New traits in corn, wheat, and rice to produce higher yields and higher profit margins for farmers.

The company is also developing herbicide-tolerant alfalfa, blight-resistant potatoes, improved yield soybeans...

It's even working on developing technology for improving the supply chain of animal products!

And get this...
Plants treated with this technology are not considered GMOs by the FDA.

The reason? No foreign elements are introduced from gene editing. It’s simply a matter of identifying a gene responsible for an unwanted trait and “snipping” it away.

In contrast, Monsanto makes its crops resistant to Roundup through genetic modification. This is why its crops are called GMOs — genetically modified organisms.

Monsanto's technology involves inserting genes from other organisms, usually bacteria, into crops in order to make them immune to Roundup.

Now, because the FDA wants to make damn sure that these crops aren’t harmful, it requires a lengthy review process that typically takes 13 years and costs $130 million to complete.

tao-death-monsanto-comparison

Our little company’s gene-editing technology? Typically, the review process for its crops takes between three to six years and costs far less.

This means that its products get onto the market up to four times as fast.

And, unlike Monsanto’s GMOs, these products are good for farmers and consumers.

Farmers using this company’s gene-editing technology get higher crop yields without having to douse them with Roundup.

Instead, they’re “edited” to train their own immune systems in warding off pests and environmental disasters.

Results for farmers? They get higher yields, lower overhead, and make more money.

Results for consumers? They get food products with more nutrition, higher fiber, and less gluten — all at a lower cost.

So, what would you rather eat: Food from crops drenched with a chemical that WHO and renowned researchers say is a probable carcinogen or food without it?

And more to the point, what would you rather invest in: the company that's responsible for the probable carcinogen, or an innovative company that's developing an array of healthy food products without involving the introduction of foreign genes?
This little company's turning the agribusiness sector on its head.

And as I said, today, you can get shares of the company for about $10.

The big boys are already in on the action, including Jefferies, Wells Fargo, and Citigroup.

And it's not surprising as this company’s gene-editing technology:

    Explodes crop yields.

    Develops crops that are resistant to drought, pests, weeds, and other environmental disasters.

    Creates food products that are more nutritious than the standard, like high oleic soybeans, low gluten wheat, and cold-storage potatoes.

And this technology can be used on any plant, giving it the potential to solve crop shortages and world hunger in the process.

Can you see what’s at stake here?

I sure do. In fact, I’m convinced that it could make you gains of up to 181-to-1.

That’s 18,100%, turning every $1,000 into $181,000.

This unbelievable opportunity reminds me of a similar biotechnology stock that went ballistic some years back...
The Illumina Story

double-down-arrow-white

The year is 1997. The location? A small pub in Cambridge, England.

Two scientists are hovering over drinks and are engaged in an animated discussion about a revolutionary biotechnology called gene sequencing.

They knew that gene sequencing was the key to developing individualized medical treatments for cancer and other diseases.

And they were determined to perfect it.

Fast forward to 2001.

Having made significant progress over the previous four years, the two scientists approach venture capitalists to fund further research.

They succeed, securing 12 million pounds — enough to build a management team for their new company, Solexa.

Six years later, a sleepy little U.S. biotech called Illumina buys it out.

The purchase lights a fire under Illumina’s share prices as it gives the company access to the world’s preeminent team of gene-sequencing researchers.

As of this writing, shares fetch $194.25. And today, the company is one of the 10 biggest biotechs in the U.S.

Two months before the buyout, shares were $16.52.

Getting in at that price would have given you a gain of 1,075.8%, turning your $1,000 investment into $10,758.

tao-death-monsanto-illumina1

A solid tenbagger — not bad, right?

But early investors made life-changing gains from Illumina’s rise from nothing.

See, in 2003, three years before the buyout, shares were going for as low as a buck apiece.

Getting in at a dollar would have you up 38,850% as I write this, transforming your $1,000 into $388,500 and your $10,000 into over $3.89 million.

Imagine a $10,000 investment making you a millionaire nearly four times over.

tao-death-monsanto-illumina2

And this, my friend, is the power of getting on board with disruptive biotechnology ahead of the crowd.

And it's the profit potential of the little $10 stock that’s keeping Monsanto executives up at night.

A few short weeks ago, the company went public, giving investors the opportunity to reap a legacy of wealth that I’ve calculated to be worth up to 18,100% — a 181-to-1 moon shot.
This is how I arrived at the 181-to-1 figure.

It’s really pretty simple.

Right now, Monsanto is a $51.7 billion megacorporation.

The little company in the process of rendering it obsolete has a valuation of about $280 million, as of this writing.

Based on these numbers, if this company were to grow to the size of Monsanto, its share prices would likely go up proportionately — 181-to-1.

That’s 18,100% turning your $10,000 into a cool $1.81 million.

Now, maybe the idea of this company becoming the next Monsanto seems like a pipe dream.

But I’m here to tell you that...
In the world of biotechnology, microcaps explode into billion-dollar companies time and time again.

There are so many biotech companies that have risen from microcap to multibillion-dollar corporations, so I don’t know where to begin...

Take Amgen Inc., which went from $0.10 to $170.04. This would have been an unheard of gain of 170,300%, which would have transformed a modest $1,000 investment into $1.7 million.

$10,000? Try $11.7 million on for size:

tao-death-monsanto-amgen

Gilead Sciences, Inc. was another huge winner. In this case, going from $0.61 to $117.86, a gain of 19,221% that would have turned a measly $1,000 into $192,210:

tao-death-monsanto-gilead

Then there was Celgene Corporation, which rose from next to nothing at $0.29 to $131.25, an incredible 45,158% gain that transformed $1,000 into $451,580:

tao-death-monsanto-celgene

Biogen Inc.'s ridiculous rise from $0.41 to $422.24 was an amazing 102,885% gain that would have made you over $1 million for every $1,000 invested:

tao-death-monsanto-biogen

Regeneron Pharmaceuticals, Inc. was another one for the books, going from $3 to $557.39 — an 18,479% winner:

tao-death-monsanto-regeneron

I could go on like this all day, but you get the picture.

The point is that dozens of biotech stocks have made millionaires of everyday investors just like you.

And I’m convinced that the little company rendering Monsanto obsolete will, as well.

But I understand if you think a 181-to-1 gain is doubtful.

Okay, fine... So, let’s say it only does one-tenth of that.

Well, at 18-to-1, you’re looking at turning a $10,000 investment into $181,000.

That would be a nice boost for your retirement fund, wouldn’t it?
This kind of profit potential can’t happen without great management.

Say what you want about Monsanto, but you can’t deny that it's been on one hell of a run.

The stock’s risen from $13.30 to $117.01 between Oct 1, 2000, to August 17, 2017.

This is a rise of 780% — a winner in anyone’s book.

"Joining the team will enable me to lead... one of the most innovative and dynamic companies in the agricultural biotech industry to date."

— A former Monsanto executive who is now CEO of the little $10 company that's pioneering gene-editing technology.

You don’t get that kind of growth without great management, and Monsanto’s been blessed with some of the most driven executives in the biotech space.

These are men with incredible vision.

And this is why two of them quit their previous roles in order to join the little company that’s turning the agribusiness world upside down with its patented gene-editing technology.

The first Monsanto executive to jump ship has 17 years of experience in developing and bringing new agricultural biotech products to market.

In his role at Monsanto, he led teams of researchers in the early discovery of these products through every commercialization phase.

He was also the program director of corporate strategy, and it’s not a stretch to say that his efforts played a huge role in Monsanto’s 780% rise.

Now, he’s the CEO of the tiny biotech company that's making his former employer obsolete.

"I believe gene editing represents the next big wave of innovation that will mark the future of food and agriculture and am excited to join [the company] as a pioneer in this space."

— The former Monsanto director of investor relations and new CFO of the $10 company making Monsanto obsolete.

The other executive who joined our gene-editing pioneer was Monsanto’s North America supply chain finance lead.

This man also served as Monsanto’s director of investor relations and as director of finance for the company’s Latin America north division.

All told, he has over 20 years of experience in the agricultural seeds and traits space.

Now, he’s our little company’s chief financial officer, and you can bet that all his experience will accelerate Monsanto’s demise.

Like the former Monsanto executive I just told you about, he left because he sees gene editing as the wave of the future.

Poaching these two executives from Monsanto was a fine start for the disruptive little biotech behind it all.

But as you’ll see, the company's raids on elite biotech executives was just getting started...
Other agricultural biotech execs are now on our little company’s dream team.

The Millennial Market

The key to unseating Monsanto

"[Millennials] would rather eat something healthy, something they can connect to, rather than what is handed to them by big branded companies," said the new chief commercial officer of our $10 gene-editing pioneer. "They buy smaller, more local brands that they connect to... and that is where [our company] is uniquely positioned."

He was the vice president of food ingredients at Cargill, a 150-year-old agricultural biotech that’s the largest private corporation in the U.S.

A plum job, to be sure.

But when the company that's pioneering new agricultural gene-editing technology approached him to be its chief commercial officer, he couldn’t resist.

It was a tremendous coup as his track record for growing Cargill's business is legendary.

Case in point: At Cargill, he led a commercial enterprise team that tripled bio-based products revenue to over $1 billion.

He also led Cargill’s industrial biotech equity investments, which included raising $600 million to build a commercial-scale aquaculture nutrition plant.

Altogether, he has over 20 years of experience in business and market development for Cargill.

Now, he’s leveraging it and all his connections in order to accelerate the demise of Monsanto.

Another key acquisition is the company’s new executive VP of corporate development and general counsel.

This man was the former chief legal officer and VP of business development for the Stine Seed Company, the largest supplier of soybean genetics in the U.S.

While there, he executed numerous acquisitions of seed trait technologies, seed genetics, and other agricultural-based biotechnologies.

And finally, there’s the company’s new VP of breeding.

He spent 16 years as the global head of soybean breeding for Syngenta, a Swiss biotech that produces agrochemicals and seeds and also conducts genomic research.

On top of this all-star list of agribusiness executives, the coinventors of the company’s patented gene-editing technology are on board as the chief operations officer and chief science officer.

As you can see, this is a management team with a proven track record of success.

And it's a prime reason why Wells Fargo, Jefferies, and Citibank got on board with this company early on in the game.

Join them and you could make up to 181 times your money as the company works to make Monsanto’s GMOs obsolete.
I want to give you a report on this company for free.

double-down-arrow-white

If you’re still here, then you clearly want to jump on this extraordinary profit opportunity.

That’s good.

But know this — there isn’t a moment to lose.

The stock shot up 28% on the day it went public a few weeks ago.

As soon as mainstream investors realize what this company’s up to and as early birds snap up shares, the ridiculously cheap price at which you can get this stock will be gone.

And this is why I’d like to send you a free report on this company.

tao-death-monsanto_report

I call it "How to Make up to 181 Times Your Money From the Death of Monsanto."

You can have it in your inbox, at no charge, in just a few minutes from now.

All I ask in return is that you start a trial subscription to my Technology and Opportunity newsletter.

Technology and Opportunity is my research and advisory service. It’s where I disclose all the details on the hottest technology investment opportunities that few in the world know about.

In exchange for your test drive, I’d like to send you my free report, called "How to Make up to 181 Times Your Money From the Death of Monsanto."

And if you agree to this deal, you’ll have access to far more than just this report...

You’ll also get:

    Twelve monthly issues. All issues are jam-packed with new and exciting research on the hottest technology companies on earth. In each month's issue, I introduce you to a breakthrough company that has the potential to change the world. You get the name of the company and specific buy instructions — and also sell instructions for when it’s time to take profits.

    Portfolio updates. When necessary, I’ll send you a market pulse update to let you know what’s happening in the world of technology and give you up-to-the-minute analyses on each of my recommendations.

    Weekly curated content. Each week I’ll share with you the most important financial and tech news from around the world in our exclusive “This Week in Tech” series. This way, you’ll be able to stay up to date on all the latest tech breakthroughs and innovations — even before they hit the public market.

    Flash alerts. I monitor the markets every day to keep a close watch on every one of my recommendations. So, if something changes with any of our positions, you’ll be the first to know.

    Unlimited access to our private, members-only website. Read all our back issues and reports and also stay current on all the cutting-edge opportunities I dig up.

    A complimentary subscription to Wealth Daily. This is where some of the best investment minds on the planet will bring you market insights and commentaries to help you make sense of today’s crazy investing environment.

And of course, you’ll also get the free and immediate opportunity to profit from the agricultural biotech play in the special report I’d like to send you.

In a second, I’m going to show you how simple it is to sign up for Technology and Opportunity and to get this free report, "How to Make up to 181 Times Your Money From the Death of Monsanto."

But first I want to you to know...
There’s another biotech in this report that stands to make you profits of an even greater measure.

Like that $10 agricultural biotech I’ve been telling you about, this firm’s changing our world for the better through gene editing.

But with humans instead of crops...

See, gene editing works on people as well as plants.

The story of little Layla illustrates just how well.

When she was 11 months old, she fell ill with leukemia.

Physicians only gave her a 25% chance of surviving.

Desperate, her parents turned to a doctor who was willing to try an experimental gene-editing treatment.

Now, two years later, their daughter is as healthy as any other toddler.

Gene editing “deleted” her cancer cells and saved her life.

And the company I just mentioned is at the forefront of bringing medical gene editing to the mainstream.

Most people aren’t familiar with this firm.

But they soon will be.

And right now, this company is developing a gene-editing technique that targets cancer and genetic diseases like cystic fibrosis, muscular dystrophy, and sickle cell anemia.

To say the biotechnology behind these techniques is groundbreaking would be an understatement.

In fact...
MIT Technology Review called it the "Biggest Biotech Discovery of the Century."

Juno Therapeutics wouldn’t argue. It's why the $3 billion biopharmaceutical giant is partnering with the company to bring gene-editing cancer treatments to market.

Treatments like the one that saved Layla.

Right now, Jefferies just upgraded the stock to a “Buy,” the same rating that Chardan Capital has for it.

And Vetr Crowd, a platform that crowdsources ratings for the stock market, just upgraded its recommendation to a "Strong Buy."
Bill Gates is a big believer in this company, as well.

And it's why he joined a group of investors that included Google Ventures, Fidelity, Deerfield Management, and T. Rowe Price and also put up $120 million to help launch the company.

This stock has the same kind of profit potential as the $10 agricultural biotech that’s killing Monsanto.

Armed with both of these stocks, your portfolio will have both sides of the gene-editing world covered.

You’ll be covered in the world of agricultural gene editing with the biotech that’s making Monsanto obsolete.

And you’ll also be covered in the world of medical gene editing with the company that Bill Gates and friends have poured $120 million into.

Bottom line: This stock has the potential to be the next Amgen, which has gone up an absurd 170,300%.

You’ll get everything that you'll need to know about investing in both gene-editing companies for free in your "How to Make up to 181 Times Your Money From the Death of Monsanto" report — just for agreeing to start a trial subscription to Technology and Opportunity.

But that’s not the only report I’d like to send to you...
Free bonus report No. 2: "The End of Google as We Know It: How You Can Profit From the Next Leap in AI."

double-down-arrow-white

tao-end-of-google-alt_report

Bill Gates calls it the “holy grail.”

Jeff Bezos says it’s “gigantic.”

And Elon Musk has poured $1 billion into it.

I’m talking about the next generation of artificial intelligence (AI). And right now, Apple, Google, Facebook, Amazon, IBM, and virtually every other high-tech titan is working day and night to bring it to life.

The biggest application for this breakthrough?

The personal digital assistant.

This breakthrough technology will make typing a question into Google Search as obsolete as dialing a rotary telephone.
Your new PDA will be like having a friend by your side who knows everything.

And they’ll exist for one purpose — to share their knowledge with you.

Just ask a question or give a command and bingo — your digital friend will provide you with all the information you need.

Not only that, but they’ll also be more than happy to schedule your meetings, plot your monthly budget, reserve your rental car, make a tee time, and email your friends.

The list of things they’ll be able to do for you will be limited only by your imagination.

And it won’t just be everyday users like you who will take advantage of these new PDAs...

Hospitals will be able to use them to more accurately diagnose patients, college students will be able to use them in place of textbooks, and businesses will be able to use them to spot marketing trends ahead of the competition.
I know that all of this sounds like something from a sci-fi fantasy, but consider how...

    IBM’s Watson can diagnose cancer faster — and more accurately — than doctors today.

    Amazon’s Echo can perform 7,000 unique skills.

    Google’s Google Assistant can already carry a two-way conversation.

    Microsoft’s Cortana can draft emails and schedule daily appointments.

These developments are just the beginning of where the next generation of PDAs will take us.

And it’s happening fast.

In fact, comScore estimates that by 2020, more than half of all internet searches will be done through voice recognition.

By then, spending in the field of PDA development will explode to $47 billion — that’s a jaw-dropping growth rate of 55.1% a year!
You can profit up to 12,284% from this historic leap in AI.

It's exactly how much money-savvy investors made on the back of Google’s IPO.

But they didn’t make it through Google — they made it through Dell, Logitech, Intel, and HP.

These are the companies that produced the hardware Google needed to scale up its search technology (the computers, mice, microprocessors, and keyboards necessary for you and me to search the Web).

If you would have invested $2,500 in each of these companies the day of Google's IPO — and sold them just 18 months later — you would have made a fortune of about $1.24 billion.

That’s a 12,284% gain.
Today, you have another shot at a million-dollar payday with the next generation of PDAs.

But not through the tech titans developing them, like Apple, IBM, and Amazon.

The million-dollar payday I’m talking about involves a $16 company that’s revolutionized voice recognition through a breakthrough called “arrays.”

Arrays are tiny microphones clustered into one device.

And they do a much better job at distinguishing distance, cutting out background noise, and identifying commands than typical microphones do.

This $16 company controls 59% of the market for these powerful little mics and is the unquestioned leader in the technology behind them.
Bottom line: Demand for this company’s mics will explode.

And it's because they’re crucial for developing the technology that will enable the high-tech industry in making PDAs mainstream.

In fact, a research report by IHS Technology says the number of microphones sold every year will nearly double from 3.6 billion to 6 billion by as soon as 2019.

The bottom line is that what we’re witnessing now is like the computer market from 1989 to 1999 when it shot up from 15% to 51%.

And now, the same thing’s about to happen with PDAs.

Can you see why right now is the perfect time to invest in this little $16 company?

It’s an extraordinary profit opportunity that can make you a millionaire, and you’ll learn everything you need to know about it in "The End of Google as We Know It: How You Can Profit From the Next Leap in AI."

And here’s another report I’d like to send you...
Free bonus report No. 3: "Ride the Robot Revolution for 50 Times Your Money"

double-down-arrow-white

tao-robotrevolution_report

In your third free bonus report, I let you in on three emerging robotics stocks with enormous growth potential.

As a recent Oxford University study concluded, 45% of all jobs are vulnerable to automation.

You can already see this tremendous force of change...

Poker rooms in Reno no longer have dealers.

Grunt work at law firms is being done by software, not ambitious young lawyers.

And Amazon's Kiva robots have already replaced tens of thousands of warehouse workers.

The creative and destructive power of robots is at a tipping point.

Fortunes will be made and lost, and it’s time for you to be on the right side of the action.

After all, we’ve already seen some incredible gains in the robotics field.

    Intuitive Surgical, a company that creates robots for the medical field, handed investors a 9,036% gain:

tao-death-monsanto-isrg

And its share price continues to rise.

    ABB Ltd, an automation company, has seen 2,288% gains.

    Cognex Corporation, a firm that makes sensors used in assembly robots, has soared 5,269%.

    Rockwell Automation, an industrial robotics company, has seen 1,791% gains.

Right now, this mind-blowing new technology is quietly changing life as we know it.

In fact, it’s transforming the global economy and minting a slew of new millionaires in the process.

I detailed everything that you need to know to join the ranks in my free report: "Ride the Robot Revolution for 50 Times Your Money."

And here’s yet another bonus for you today...
Free bonus report No. 4: "The Next Intel: Banking up to 6,400% From the Death of the iPhone."

double-down-arrow-white

tao-next-intel_report

In your fourth free bonus report, I let you in on a little tech firm that's poised to unseat Apple from the top of the tech industry food chain.

You see, this tiny tech firm is the one behind a bold new product that many are now calling the "iPhone killer."

Mark Zuckerberg says the iPhone killer is "the obvious next step."

In fact, he believes so strongly in this disruptive technology that he’s gone on record saying it will one day be used by "billions of people" across the world.

And as it turns out, Zuckerberg isn't the only one with his sights set on this game-changing product. Microsoft and Google are now after it, too, and they’ve been working in top secret labs to produce their own versions.

They're also spending billions of dollars to make this technology a reality.

But here's the real kicker...

One little-known tech stock has found its way into not one, not two, but all three of the iPhone killer devices that are currently in development.

Point blank: This company has gotten into position like Intel did during the period leading up to the PC revolution. And investors stand to turn an enormous profit, which I’ve calculated to be worth up to 6,400%.

It may sound crazy, but I assure you that it's all true.

You can find out everything you need to know about it in your free bonus report, "The Next Intel: Banking up to 6,400% From the Death of the iPhone."

And you can get it, at no cost, simply by giving Technology and Opportunity a risk-free try.
I make my subscribers a lot of money in Technology and Opportunity.

And I’m not talking tiny 1% wins, either.

So far, in 2017, I have an 87.5% winning percentage — 7 for 8 in closing positions.

The biggest winner is a 637.9% home run — after just two months — on Ethereum, the digital “currency” taking the financial world by storm:

tao-death-monsanto-ethereum

We also took 89.7% profits on Amazon in only 16 months:

tao-death-monsanto-amazon

And 74.85% on iRobot Corporation:

tao-death-monsanto-irobot

Altogether, my overall profits in 2017 have more than doubled to 110.54%.

And as I write this, we’re sitting on a number of other substantial gains:

    41.18% on a solar company with a strong presence in China.

    35.04% on a digital transformation provider.

    54.01% on a semiconductor provider.

    37.98% on a motion and control technology developer.

    35.61% on an automated industrial solutions developer.

    37.13% on a designer, developer, and manufacturer of automatic test equipment.

    59.02% on a company that provides design, engineering, and manufacturing services for original equipment manufacturers around the world.

    27.65% on a numeric control services and robotics company.

Obviously, I deliver consistent gains...

But don’t just take my word for it...

"I could not believe it. Yes! I had $5K on FMI. Now it’s $10K! Best I've ever done in the market. Thanks a lot!"

— Harry M.

"Took this recommendation but bought only 144 shares. Doubling your money is always good, but this one paid my subscription many times over."

— Larnard S.

"Technology and Opportunity has lifted my spirits in more ways than one: a coordinated and literate research publication, factual and thorough, your research has allowed me to make a definitive decision on the best course of action."

— Tim B.

"Well, after 26 years of investing, I finally had a stock get 'bought out,' and it feels great! I bought on your recommendation, and I'm selling now based again on your recommendation. The timing couldn't be better — I'm scheduled to have my Tesla Model X delivered just after the New Year and I've been trying to figure out how to pay for it."

— Jonathan C.

No doubt — doubling your money is great and profiting to the tune of a new car is even better.

But I’ve calculated that the agricultural gene-editing play I’ve been telling you about will be worth $181,000 on a $1,000 grubstake or even more if you take a bigger position.

And the medical gene-editing company could be worth even more than that.
Quite simply, this is your chance to finally hit the windfall of your dreams.

I’m dead serious. Your chances of retiring on the spot are staring you in the face.

All you have to do is run with this opportunity.

If I were dreaming up the perfect environment for banking the biggest profits that most of us have ever seen...

The current biotech opportunity in gene editing is damn close to what I’d be imagining.

And since you’re still with me, you must agree.

You'd also agree that I could easily charge thousands of dollars for this information.

What do you think a private hedge fund manager would want in exchange for revealing what stands to be one of the most lucrative investment opportunities of our time?

$5,000? $10,000? $50,000?

But I won't charge anywhere near that much.

I want everyone to have a fair shot.

And that's why I only charge $249 for a one-year subscription to Technology and Opportunity.

But you won’t even have to pay that much if you act now...
If you respond within the next 24 hours...

You can get on board for only $99.

That’s right.

For less than a nice dinner for two, you can get a full year’s worth of Technology and Opportunity, not to mention the four free reports that could turn your portfolio into a legacy of wealth:

    "How to Make up to 181 Times Your Money From the Death of Monsanto."

    "The End of Google as We Know It: How You Can Profit From the Next Leap in AI."

    "Ride the Robot Revolution for 50 Times Your Money."

    "The Next Intel: Banking up to 6,400% From the Death of the iPhone."

tao-death-monsanto-reports

In the coming weeks, I’ll be offering these reports for $249 each, but you're going to get all four of them for free — just for giving Technology and Opportunity a try.

That's $996 worth of little-known information in order to easily fund your retirement.

Here’s something else: You’re not on the hook for a thing.

This is just a trial subscription.

It’s 100% risk and obligation free.

There’s no gimmick here and no fine print, either.
For the sake of your own future, you must sign up.

Yes, I want you to sign up — even if you fully intend to collect the refund — so you can put some cash into these powerful profit opportunities before everyone else does.

Then, you can decide whether or not you're in it for the long haul.

You won't be paying a cent for the information that could end up funding your retirement.

All you’re doing is letting me hold your $99 for a month while you decide whether or not Technology and Opportunity is right for you.

But I’m positive that once you see the kinds of gains I can deliver, you’ll be a Technology and Opportunity subscriber for life.

And it's because there’s always a chance to make huge gains somewhere in the world of technology.

Bottom line: For just under a hundred bucks, you get the best technology sector investment analysis and guidance you’ll ever receive.
Warning: There’s no telling how long the price will stay this low.

Like I said, this price is only guaranteed for the next 24 hours.

After that, it’ll be $249.

Here’s something else: I promise that you’ll never pay more than $99 a year if you’re one of those first 100 people.

So, now you have a decision to make...

I’ve done everything I can do to make this a no-brainer:

    I’ve shown you how a tiny biotech company could make you up to 181 times your money.

    I've offered you three other reports on equally disruptive technologies, each of which could make you even bigger profits.

    I’ve offered you 30 full days of risk-free access to all of Technology and Opportunity’s services and benefits.

    And I’ve cut the price to an absurd $99 in order for you to start a trial subscription to Technology and Opportunity right now.

All told, you’ll be saving $1,046 by taking advantage of this offer.

So, now it’s up to you.subscribe-now-blue          

If you believe it’s worth letting me hold onto your $99 while you get inside information that could change your life, then click the order button above, before the rank-and-file investors catch wind of these opportunities and take them from you.

Cheers,

Stutman sig

Jason Stutman
Investment Director, Technology and Opportunity

P.S. If you’re not on board with these innovative gene-editing companies before the Wall Street herd catches on to them, you will have missed your best chance at life-changing wealth.

Please don’t let that happen.subscribe-now-blue

Angel Publishing LLC, a general interest newsletter is not liable for the suitability or future investment performance of any securities or strategies discussed. Please note that we are not a registered investment firm or broker/dealer. Only a registered broker or investment adviser may advise you individually on the suitability and performance of your portfolio or specific investments.

Readers are advised that the material contained herein should be used solely for informational purposes. As a publisher of a financial newsletter of general and regular circulation, we cannot tender individual investment advice. We urge you to always conduct your own research and due diligence and obtain professional advice before making any investment decision.

We will not be liable for any loss or damage caused by a reader's reliance on information obtained on our web sites. Our readers are solely responsible for their own investment decisions. Historical investment return examples given are hypothetical, and not to be taken as representative of any individual's actual trading experience. Please click here to see our Details and Disclosures